Natalie Vaninov
About Me
I graduated in 2014 from Smith College studying Organic Chemistry and writing a thesis on a novel method for the synthesis of steroid backbones. For the last five years, I've worked on the R&D team of a small biotechnology startup based in Greater Boston Area called Sentien Biotechnologies (http://www.sentienbiotech.com).
Sentien's Clinical product, the SBI-101, is a hollow-fiber device seeded with allogeneic, bone-marrow derived mesenchymal stem cells (MSCs). The cells are immobilized within a blood filtration device and integrated into a standard dialysis circuit, allowing for controlled delivery of MSC-secreted factors and extracellular vesicles. The intended use for SBI-101 is to treat diseases plagued by systemic inflammation like acute kidney injury, amyotrophic lateral sclerosis, and acute myocardial infarction. I have spent much of my time working on device characterization and bioassays to assess MSC-seeded device performance under varying conditions.
This experience prompted me to seek out a PhD focused in Immunology at Icahn School of Medicine starting in 2019.
Language
Position
Research Topics
Biomedical Sciences, Cellular Immunity, Immunology, Immunosuppression, Inflammation, Signal Transduction, Translational Research
Multi-Disciplinary Training Areas
Immunology [IMM]
About Me
I graduated in 2014 from Smith College studying Organic Chemistry and writing a thesis on a novel method for the synthesis of steroid backbones. For the last five years, I've worked on the R&D team of a small biotechnology startup based in Greater Boston Area called Sentien Biotechnologies (http://www.sentienbiotech.com).
Sentien's Clinical product, the SBI-101, is a hollow-fiber device seeded with allogeneic, bone-marrow derived mesenchymal stem cells (MSCs). The cells are immobilized within a blood filtration device and integrated into a standard dialysis circuit, allowing for controlled delivery of MSC-secreted factors and extracellular vesicles. The intended use for SBI-101 is to treat diseases plagued by systemic inflammation like acute kidney injury, amyotrophic lateral sclerosis, and acute myocardial infarction. I have spent much of my time working on device characterization and bioassays to assess MSC-seeded device performance under varying conditions.
This experience prompted me to seek out a PhD focused in Immunology at Icahn School of Medicine starting in 2019.
Language
Position
Research Topics
Biomedical Sciences, Cellular Immunity, Immunology, Immunosuppression, Inflammation, Signal Transduction, Translational Research
Multi-Disciplinary Training Areas
Immunology [IMM]